Physician profile
George N Eischens
NPI 1487657912
$3,502.18
in general payments reported to CMS, 2019-2025
15 companies · $713 in 2025
The $713 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $221 · 2021: $306 · 2022: $779 · 2023: $749 · 2024: $422 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $825.70 | 2020-2025 | Cequa |
| Bausch & Lomb Americas INC. | $646.79 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $314.63 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $245.51 | 2019-2020 | |
| Alcon Vision LLC | $245.02 | 2019-2025 | Precision7 |
| Johnson & Johnson Vision Care, INC. | $244.76 | 2019-2024 | Acuvue |
| Johnson & Johnson Surgical Vision, INC. | $236.86 | 2024-2025 | Tecnis Simplicity, Amo Phaco Needle |
| Biotissue Holdings INC. | $224.45 | 2023 | |
| Glaukos Corporation | $149.48 | 2022 | |
| Coopervision INC. | $109.89 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens |
| Novartis Pharmaceuticals Corporation | $105.44 | 2019-2023 | |
| Abbvie INC. | $74.75 | 2022-2025 | |
| Dompe US, INC. | $36.41 | 2022-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $23.77 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $18.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Eischens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.